20
Participants
Start Date
October 31, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
eltrombopag
"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
RECRUITING
Schneider Children's Medical Center of Israel, Petah Tikva
RECRUITING
Hadassah hospital, Jerusalem
Collaborators (1)
GlaxoSmithKline
INDUSTRY
moshe yeshurun
OTHER